ClinicalTrials.gg
Enrolling by invitationNCT03727399Updated Oct 22, 2026

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

An observational study in Pollen Allergy, sponsored by Mabylon AG. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Mabylon AG · Observational

How we know

Updated Oct 22, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

02

Conditions studied

  • Pollen Allergy
03

In context

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's planned enrollment of 300 is above the median of 86 across 32 observational studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Mabylon AG is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The project population will include adult (> 18 years) patients with a history of grass and birch pollen allergy verified by positive skin prick test and allergen-specific IgE in blood. The study population may also include patients with ongoing or completed AIT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
  • Male or female patients older than 18 years
  • Written for providing blood and also to allow experimental manipulation

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Any within the last three days
  • Oral corticosteroid therapy within the last ten days
  • Parenteral depot corticosteroids within the last three months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Interventions

  • Otherblood withdrawal

    Blood withdrawal

06

What researchers measure

Primary outcomes

  1. Antibody profiling

    Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.

    Time frame: October 2018 - September 2021

07

Study locations

1 site
  • Immunologie Zentrum Zürich
    Zurich, Canton of Zurich 8006, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2018 (actual). Primary completion is estimated for Dec 2030, 146 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2025 → Dec 2030 and completion Dec 2025 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 1, 2018
StartActual
Oct 1, 2018
Primary completionEst.
Dec 31, 2030was Dec 2025
CompletionEst.
Dec 31, 2030was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Immunologie Zentrum Zürich · Zurich, Switzerland
Show 1 removed
  • Immunologie Zentrum Zürich · Zürich, Switzerland
Oct 22, 2026
Primary completion
Dec 31, 2025→Dec 31, 2030
Oct 22, 2026
Study completion
Dec 31, 2025→Dec 31, 2030
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • Immunologie Zentrum Zürich · Zurich, Switzerland
    Show 1 removed
    • Immunologie Zentrum Zürich · Zürich, Switzerland
    Primary completion Dec 31, 2025→Dec 31, 2030
    Study completion Dec 31, 2025→Dec 31, 2030
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03727399
Lead sponsor
Mabylon AG
Responsible party
Sponsor
First posted
Nov 1, 2018
Start date
Oct 1, 2018
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion